Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Opioids and CNS depressants: Walking the fine line

Opioids and CNS depressants: Walking the fine line The U.S. Food and Drug Administration (FDA) is highly respected in the medical community, but it is, after all, a government agency, and not all of its official pronouncements are particularly newsworthy. At The Update, we try to cover the ones that convey new information we believe has the potential to meaningfully impact the practice of our readers or the well‐being of their patients. By those criteria, the Drug Safety Communication summarized in this month's issue (page 8) wouldn't seem to make the cut. It's titled “FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks.”1 Yes, that's a mouthful, but there's nothing in it that's new or surprising — it's what I would be expecting from the routine practice of our average reader. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Brown University Psychopharmacology Update Wiley

Opioids and CNS depressants: Walking the fine line

Download PDF
2 pages

Loading next page...
 
/lp/wiley/opioids-and-cns-depressants-walking-the-fine-line-zj31LLYXxC

References (1)

Publisher
Wiley
Copyright
Copyright © 2018 Wiley Periodicals, Inc., A Wiley Company
ISSN
1068-5308
eISSN
1556-7532
DOI
10.1002/pu.30286
Publisher site
See Article on Publisher Site

Abstract

The U.S. Food and Drug Administration (FDA) is highly respected in the medical community, but it is, after all, a government agency, and not all of its official pronouncements are particularly newsworthy. At The Update, we try to cover the ones that convey new information we believe has the potential to meaningfully impact the practice of our readers or the well‐being of their patients. By those criteria, the Drug Safety Communication summarized in this month's issue (page 8) wouldn't seem to make the cut. It's titled “FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks.”1 Yes, that's a mouthful, but there's nothing in it that's new or surprising — it's what I would be expecting from the routine practice of our average reader.

Journal

The Brown University Psychopharmacology Update – Wiley

Published: Jan 1, 2018

There are no references for this article.